Abstract
Background
Cardiotoxicity is the major limiting factor in anthracycline chemotherapy of advanced neoplastic disease. Epirubicin shows a more favorable therapeutic index than does doxorubicin, but it is still cardiotoxic. Limited data regarding epirubicin cardiotoxicity are available, and suggested guidelines for doxorubicin with left ventricular ejection fraction (LVEF) measurement may not be empirically useful for epirubicin therapy. This study evaluates the diagnostic role of antimyosin immunoscintigraphy for early identification of patients at risk for late pump dysfunction from cardiotoxicity induced by high-dose administration of epirubicin up to high cumulative dosages.
Methods and Results
Chemotherapy with epirubicin was administered to 36 patients with cancer at a dosing rate of 160 mg/m2 as a bolus injection every 21 days to a cumulative dosage heart-lung ratio (HLR) measurements were performed before chemotherapy, at intermediate cumulative epirubicin dosages, at the end of treatment, and during the follow-up. LVEF decreased significantly at the end of the treatment and after therapy discontinuation. HLR values were significantly increased at intermediate epirubicin dosage levels and continued to increase to the end of the treatment but thereafter remained substantially unmodified for 3 to 6 months after therapy discontinuation. A value of HLR>1.85 at intermediate epirubicin dosage level showed a sensitivity of 95% and a specificity of 57% as a predictor of late LVEF impairment.
Conclusions
LVEF appears more useful at high cumulative dosages and during follow-up to monitor late pump dysfunction, whereas HLR may be effective during the early phase of the therapy in determining which patients are at risk for development of late cardiac dysfunction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Myers CE, Kinsella TJ. Cardiac and pulmonary toxicity. In DeVita VT, Hellmann S, Rosemberg SA, editors. Cancer, principles and practice of oncology. 2nd ed. Philadelphia: Lippincott; 1985. p. 2022–32.
Young RC, Ozols RF, Myers CE. The anthracyclines antineoplastic drugs. N Engl J Med 1981;305:139–53.
Neri B, Cini-Neri G, Bandinelli M, Pacini P. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects. Adv Clin Oncol 1988;1(suppl 2):9–15.
Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818–26.
Robert J, Cersosimo J, Waun KI, Hong. Epirubicin: a review of the pharmacology, clinical activity and adverse effects of an adriamicin analogue. J Clin Oncol 1986;3:425–39.
Ganzina F. 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983;10:1–22.
Dardir MD, Ferrans VJ, Mikhael YS, et al. Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 1989;7:947–58.
Praga C, Trave F, Petroccione A. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. In: Nimows, et al, editors. Clinical measurement in drug evaluation. London: Wolfe Publishing; 1991. p. 131–42.
Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990;8:1806–10.
Joss RA, Hansen HH, et al. Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. Eur J Cancer Clin Oncol 1981;20:459–99.
Young CM. Epirubicin: a therapeutically active doxorubicin analogue with reduced cardiotoxicity. In: Bonadonna G, editor. Advances in anthracyclines chemotherapy: epirubicin. Milan, Italy: Masson; 1984. p. 183–91.
O'Brian RM, Baker LH, Gottilials JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940–7.
Bastholt M, Dalmark M, Gjedde S, et al. Epirubicin at four different dose levels in metastatic breast cancer: a randomized trial. Proc Am Soc Clin Oncol 1992;11:56.
Jones RB, Holland JF, Bhardwaj S, et al. A phase I–II study of intensive dose adriamycin for advanced breast cancer. J Clin Oncol 1987;5:172–7.
Pinedo HM, Bramwell VHC, Mouridsen MD, et al. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 1984;53:1825–32.
Neri B, Pacini P, Algeri R, et al. Conventional versus high dose epidoxorubicin as single agent in advanced breast cancer. Cancer Invest 1993;11:106–12.
Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 1987;82:1109–16.
Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med 1979;300:278–83.
Carrio I, Berna L, Ballester M, et al. Indium-111-antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection. J Nucl Med 1988;29:1893–900.
Estorch M, Carrio I, Berna L, et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 1990;31:1965–9.
Carrio I, Estorch M, Berna L, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium-111-myosin-specific monoclonal antibody studies. Eur J Nucl Med 1991;18:806–12.
Estorch M, Carrio I, Martinez-Duncker C, et al. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium-111-antimyosin monoclonal antibody studies. J Clin Oncol 1993;11:1264–8.
Carrio I, Lopez-Pousa A, Estorch M, et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 1993;34:1503–7.
Jain D, Zaret BL. Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity? J Nucl Med 1990;12:1970–4.
World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication no 48. Geneva: The Organization, 1979.
Zaret BL, Wakers FJ. Medical progress: nuclear cardiology (second of two parts). N Engl J Med 1993;329:855–63.
Isner JM, Ferrans VJ, Cohen SR, et al. Clinical and morphological cardiac findings after anthracyclines chemotherapy: analysis of 64 patients studied at necropsy. Am J Cardiol 1983;51:1167–74.
Druck MN, Gulenchyn KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984;53:1667–74.
Black DJ, Livingstone RB. Antineoplastic drugs in 1990: a review. Drugs 1990;39:652–73.
Maini CL, Ferraironi A, Sciuto R, et al. Cardiotoxicity of high dose epirubicin evaluated by angiocardioscintigraphy. Oncol Rep 1995; 2:443–6.
Speyer JL, Green MD, Kramer E, et al. Protective effects of bispiperidione ICRF-187 against doxorubicin-induced cardiotoxicity in women with advanced breast cancer. N Engl J Med 1988;319:745–52.
Herman EH, Ferrans VJ, Myers CE, et al. Comparison of the effectiveness of (+)-1,2(bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagle dogs. Cancer Res 1985;45:276–81.
Dec GW, Palcios I, Yasuda T, et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990;16:97–104.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maini, C.L., Sciuto, R., Ferraironi, A. et al. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity. J Nucl Cardiol 4, 502–508 (1997). https://doi.org/10.1016/S1071-3581(97)90008-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/S1071-3581(97)90008-8